Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
604 Results for "
SCO2 mutations
" in MedChemExpress (MCE) Product Catalog:
Products (604)
604 Results for "SCO2 mutations" in MCE Product Catalog:
Cat. No.: HY-120726
CAS No.: 1404506-35-9
BF844 mitigate hearing loss associated with USH3 (usher syndrome type III) mutation CLRN1 (clarin-1) N48K. BF844 induces CLRN1 N48K transportes to the plasma membrane. BF844 shows significantly preserves hearing in vivo .
Cat. No.: HY-184315
CAS No.: 2411873-31-7
Cat. No.: HY-P3845
CAS No.: 1802086-23-2
Target:
Research Areas:
Cat. No.: HY-P4585
CAS No.: 147335-12-4
Target:
Research Areas:
Cat. No.: HY-P991513
Target:
Research Areas:
Cat. No.: HY-130178
CAS No.: 1210501-46-4
Target:
Research Areas:
CL-385319 is an N-substituted piperidine compound with inhibitory activity against H5N1 avian influenza A virus infection. CL-385319 exhibited an IC50 of 27.03±2.54 μM against infection of highly pathogenic H5N1 virus in Madin-Darby canine kidney cells (MDCK). CL-385319 had low cytotoxicity with a CC50 of 1.48 mM and was able to inhibit the entry of pseudoviruses carrying H5N1 strains from different sources, but had no inhibitory effect on the entry of VSV-G pseudotyped particles. Pseudoviruses with the M24A mutation in HA1 or the F110S mutation in HA2 were resistant to CL-385319, indicating that these two residues in the cavity region may be critical for the binding of CL-385319 .
Cat. No.: HY-15448S1
CAS No.: 1961280-94-3
Synonyms: VX-661-d6
Cat. No.: HY-L015
1,189 compounds
The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.
MCE owns a unique collection of 1,189 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.
Cat. No.: HY-137674A
Synonyms: Isoguanosine-5'-O-triphosphate sodium
Target:
Research Areas:
isoGTP (Isoguanosine-5'-O-triphosphate) sodium is an isomer of guanosine 5'-triphosphate and a phosphorylated form of Crotonoside (HY-N0071). isoGTP sodium inhibits transcription and induces T to C mutations in a reverse transcriptase assay. isoGTP sodium is promising for research of substrate specificity of phosphofructokinase and mutT homolog 1 (MTH1) [2].
Synonyms: NVL-520; NUV-520
Target:
Research Areas:
Zidesamtinib (NVL-520) is a potent, selective, orally active and brain-penetrant inhibitor of diverse ROS1 fusions and resistance mutations, with IC50s of 0.7 and 7.9 nM for wild-type ROS1 and ROS1 G2032R, respectively, and spares TRK inhibition. Zidesamtinib can be used for the research of cancer .
Cat. No.: HY-162037
CAS No.: 2241659-94-7
CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with Ki values of 8 and 13 nM, respectively. CDDD11-8 reduces the proliferation of leukemia cell lines and was particularly effective against those harboring FLT3-ITD mutation [2].
Cat. No.: HY-162536
Target:
Research Areas:
Pan-RAS-IN-5 is a macrocyclic pan-RAS inhibitor that targets mutant RAS (including KRAS, NRAS, and HRAS). Pan-RAS-IN-5 inhibits the proliferation of various KRAS-mutant cancer cells. Pan-RAS-IN-5 is applicable to the research of KRAS mutation-related cancers such as pancreatic cancer, nephroblastoma, and colon adenocarcinoma .
Cat. No.: HY-168580
CAS No.: 2941026-35-1
c-Kit-IN-7 (Compound 104) is a potent inhibitor of c-Kit, with IC50 values of ≤10 nM. c-Kit-IN-7 inhibits the cell proliferation in GIST430 and BaF3 mutants, with IC50 values of ≤100 nM. c-Kit-IN-7 plays an important role in cancer driven by c-KIT kinase mutations research .
Cat. No.: HY-185557
CAS No.: 3063448-59-6
Target:
Research Areas:
LLC0424N is a negative control compound designed by methylating the thalidomide moiety of LLC0424 (HY-161574). LLC0424N shows does not induce NSD2 degradation and inhibit growth of acute lymphoblastic leukemia cells with NSD2 mutation. LLC0424N can be used for the research of acute lymphoblastic leukemia .
Category:
Cat. No.: HY-P99983
Target:
Research Areas:
Cat. No.: HY-W704348
Cat. No.: HY-12447
CAS No.: 765958-29-0
SMK-17 is a selective, non-ATP-competitive MEK1/MEK2 inhibitor with IC50s of 62 nM and 56 nM, respectively. SMK-17 binds to the allosteric pocket of MEK1/2. SMK-17 induces apoptosis in tumor cell lines harboring β-catenin mutations .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
